AIPPI Rapid Response: Commonwealth v Sanofi (clopidogrel)
In a long-awaited judgment, the Federal Court has denied the Commonwealth’s claim against Sanofi for compensation for alleged higher PBS subsidies paid on Plavix (clopidogrel) because Sanofi held Apotex off the generic market by an interlocutory injunction on a patent that was ultimately determined to be invalid.
We bring together a panel of experts to discuss the outcome, the Court’s reasoning, emerging themes in the recent caselaw and implications for pharmaceutical patent cases in the coming years.
Our panellists are:
James Hutton of 11 Wentworth, who acted for Sanofi in defending the Commonwealth's clopidogrel compensation claim;
Kellech Smith of Ashurst, who acted for Apotex in its case which invalidated the clopidogrel patent and in Apotex's own claim for compensation from Sanofi in relation to clopidogrel;
Matt Swinn of King & Wood Mallesons, who acted for Sigma in its recent compensation claim relating to venlafaxine.
When: 21 May 2020; 5.00pm - 6.15pm
Where: By WebEx - details provided in a confirmation email following registration
Cost: Free for AIPPI members; $30 for non-members
We hope to see you online!
Improving and promoting the protection of intellectual property on both an international and national basis.
© Copyright 2021 AIPPI Australia